The nation of Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) over five years because of Washington's request for sensitive biological samples.
The decision became public after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official representative has since stated that the US was seeking genetic material for scientific study and commercial purposes while was not willing to share the benefits from future treatments.
"We must now begin the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further negotiations to reach a agreement agreeable to both sides so the nation's vital HIV programme can continue.
Wider Background
This development follows a similar situation in neighbouring Kenya, where a high court blocked a similar deal with the US following concerns were filed about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
As per reports, 16 African countries have to date signed similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be accessible to our population should a new pandemic emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending systems previously established via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This system is intended to guarantee that when a nation provides its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent collaboration could be arranged in a manner that respects the independence and dignity of both nations."
Medical Community Reaction
Medical experts said it recognised the official position, but urged that negotiations should continue since much of the country's HIV programmes depended on foreign aid.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the complex debate between accepting crucial international aid and protecting national sovereignty in an ever more interconnected world.